To develop breast cancer therapies, the targeting of estrogen receptor-α (ERα), which is expressed in ~70% of breast cancers and which makes it difficult to obtain a response to cancer drug treatment (13,14), requires consideration. This evidence concerns the gene ESR1 and breast cancer.